BDNF TrkB- and beta-AR signals in ischemic and non-ischemic cardiomyopathy
缺血性和非缺血性心肌病中的 BDNF TrkB- 和 beta-AR 信号
基本信息
- 批准号:9447993
- 负责人:
- 金额:$ 59.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-01-11 至 2021-12-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcuteAdrenergic ReceptorAdrenergic alpha-AntagonistsAgonistAnimal ModelAttenuatedBindingBrain-Derived Neurotrophic FactorCanis familiarisCardiacCardiac MyocytesCellsChronicClinicalCollaborationsCoupledDataDilated CardiomyopathyDown-RegulationEtiologyFosteringFunctional disorderG protein coupled receptor kinaseGenerationsGoalsHeartHeart ArrestHeart DiseasesHeart failureHumanImpairmentInfusion proceduresInjuryKnock-outKnockout MiceLeftLeft ventricular structureMetabolicMetabolismMetoprololModelingMusMuscle CellsMyocardialMyocardial InfarctionMyocardial IschemiaMyocardiumNeurotrophic Tyrosine Kinase Receptor Type 2OutcomePathologicPeptidesPhosphotransferasesPhysiologicalPreventionProductionProteinsRelaxationResearchSignal TransductionStressSymptomsTestingTherapeuticTherapeutic AgentsTransgenic OrganismsTropomyosinUp-RegulationVentricularclinically relevantdesensitizationdesignfunctional outcomeshemodynamicsimprovedinhibitor/antagonistnoveloverexpressionpre-clinicalpreventreceptorresearch clinical testingsphingosine 1-phosphatetherapeutic target
项目摘要
Brain-derived neurotrophic factor (BDNF) and its associated, specific tropomyosin related kinase B (TrkB)
receptor modulates basal myocardial function and low circulating BDNF levels correlate with worsening of
symptoms in heart failure (HF) subjects. Deleting BDNF in myocytes leads to prominent LV dilation at baseline,
but basal and stress-stimulated left ventricle (LV) function was never tested in cBDNF-/- mice. Our pilot data
suggest that left ventricles from human and experimental HF subjects are massively BDNF depleted. Despite
this experimental and clinical evidence, cardiac BDNF/TrkB remains largely understudied. The long-term goal is
to determine factors accounting for loss in BDNF/TrkB signal in failing hearts, and mechanisms whereby re-
introducing BDNF via TrkB stimulation in BDNF-depleted failing hearts affords protection against ischemic and
non-ischemic stress. Here we advance the following three novel hypotheses: 1) that myocardial BDNF
generation prevents chronic cardiac decompensation in infarcted hearts, and proper βAR activity is involved
in this generation; 2) that direct S1PRs stimulation enhances myocardial BDNF production, preventing LV
decompensation in infarcted mice, and that selective β1AR-blockers rescue β3AR down-regulation in post-MI
hearts, increasing myocardial BDNF levels via β3-AR/S1PRs signal; 3) that cardiac TrkB stimulation rescues
β-AR sensitivity and improves decompensation in a dog model of non-ischemic cardiomyopathy.
The rationale for the proposal is that understanding how loss in BDNF/TrkB signal contributes to myocardial
adaptation to ischemic or non-ischemic cardiac stress will advance efforts to therapeutically harness this capacity
for clinical relevant conditions associated to loss of cardiomyocytes due to ischemic or non-ischemic cardiac
diseases. The central hypotheses will be tested in three integrated Specific Aims. In Aim 1, we will determine
if deleting myocardial BDNF worsens outcome in mice with myocardial infarction, and to test whether TrkB
agonists rescues BDNF expression and β-AR sensitivity in infarcted hearts, the latter by inhibited GRK2, the
major kinase liable for cardiac β-AR desensitization. In Aim 2, we will test if direct β3-AR or S1PRs stimulation
enhances myocardial BDNF content to protect the myocardium against myocardial infarction; In Aim 3, we will
test whether the chronic infusion of TrkB agonists rescues LV function in dogs with tachypacing-induced HF via
improved myocardial efficiency and restored β-AR sensitivity. The proposed research is significant, because
it is expected to foster our understanding of a novel compensatory mechanism, BDNF/TrkB signal that can
enable the heart to preserve functional integrity and energetic efficiency in myocardial cells under condition of
ischemic or non-ischemic stress, and to determine whether TrkB agonists merit further consideration for clinical
testing in HF.
脑源性神经营养因子(BDNF)及其相关的特异性原肌球蛋白相关激酶B (TrkB)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nazareno Paolocci其他文献
Nazareno Paolocci的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nazareno Paolocci', 18)}}的其他基金
BDNF TrkB- and beta-AR signals in ischemic and non-ischemic cardiomyopathy
缺血性和非缺血性心肌病中的 BDNF TrkB- 和 beta-AR 信号
- 批准号:
10287657 - 财政年份:2018
- 资助金额:
$ 59.24万 - 项目类别:
Nitroxyl cardiac effects are mediated by cAMP/PKA signal
硝酰心脏效应由 cAMP/PKA 信号介导
- 批准号:
7433770 - 财政年份:2005
- 资助金额:
$ 59.24万 - 项目类别:
Nitroxyl cardiac effects are mediated by cAMP/PKA signal
硝酰心脏效应由 cAMP/PKA 信号介导
- 批准号:
7101684 - 财政年份:2005
- 资助金额:
$ 59.24万 - 项目类别:
Nitroxyl cardiac effects are mediated by cAMP/PKA signal
硝酰心脏效应由 cAMP/PKA 信号介导
- 批准号:
7255482 - 财政年份:2005
- 资助金额:
$ 59.24万 - 项目类别:
Nitroxyl cardiac effects are mediated by cAMP/PKA signal
硝酰心脏效应由 cAMP/PKA 信号介导
- 批准号:
6926499 - 财政年份:2005
- 资助金额:
$ 59.24万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 59.24万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 59.24万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 59.24万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 59.24万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 59.24万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 59.24万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 59.24万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 59.24万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 59.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 59.24万 - 项目类别:
Operating Grants














{{item.name}}会员




